Patients with HCC, prostate cancer, colorectal cancer and breast cancer were studied, and with the exception of breast cancer, T-cell reactivity to BMI-1 and/or EZH2 was observed in all groups. This evidence concerns the gene EZH2 and breast carcinoma.